ஆரோக்கியம் அறிவியல் கையகப்படுத்தல் கார்ப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dive Brief:
Roivant Sciences, an unusual holding company with roughly a dozen biotech subsidiaries, will go public through a merger with a blank-check entity in a deal that values the company at $7.3 billion.
Roivant will get $611 million in cash by merging with Montes Archimedes Acquisition Corp., a special purpose acquisition company, or SPAC, formed by Patient Square Capital. That figure includes $411 million already in a Montes Archimedes Trust and a commitment by Patient Square and other investors to buy $200 million in Roivant stock at $10 apiece.
The agreement will leave Roivant, whose subsidiaries have had both high-profile successes as well as failures, with $2.3 billion in cash upon going public. The deal, one of the larger SPAC mergers in biotech, comes amid signs the boom in such deals may be waning. Returns are down, while many SPACs are in competition for takeover targets. Federal oversight, meanwhile, appears to be increasing. ....

Sumitomo Dainippon Pharma , Vivek Ramaswamy , Matthew Gline , Axovant Sciences , Exchange Commission , Roivant Sciences , Puretech Health , Montes Archimedes Acquisition Corp , Montes Archimedes , Centessa Pharmaceuticals , Health Sciences Acquisition Corp , Dive Brief , Patient Square , Montes Archimedes Trust , Sumitomo Dainippon , Sio Gene Therapies , Arbutus Biopharma , Sciences Acquisition , Financial Times , விவேக் ராமசாமி , மேத்யூ கிளினே , பரிமாற்றம் தரகு , றொய்வன்ட் அறிவியல் , மான்டஸ் ஆர்க்கிமிடீஸ் கையகப்படுத்தல் கார்ப் , மான்டஸ் ஆர்க்கிமிடீஸ் , ஆரோக்கியம் அறிவியல் கையகப்படுத்தல் கார்ப் ,